FogPharma, a pioneering biopharmaceutical company at the forefront of transformative drug development, has successfully raised an impressive $145 million in its latest funding round. This significant investment underscores the growing confidence in FogPharma’s innovative approach to drug discovery and its groundbreaking HeliconTM peptides—a new class of drugs designed to overcome the limitations associated with existing precision medicines. These peptides uniquely blend the broad targeting capabilities of monoclonal antibodies with the exceptional cell-penetrating properties of small molecules, paving the way for unprecedented treatment options across a wide array of human diseases. With this fresh capital, FogPharma aims to accelerate the development and commercialization of its HeliconTM peptide platform, striving to deliver universal druggability and to tackle nearly all human disease drivers with remarkable speed and scalability. As the company continues to expand its scientific and operational capabilities, this funding will also support vital research efforts and the enhancement of its technological infrastructure. FogPharma is committed to revolutionizing the landscape of therapeutic development, and with this funding milestone, it is well-positioned to bring about significant advancements in healthcare. Investors and stakeholders alike are excited to see how FogPharma will leverage this funding to propel its mission of creating accessible and effective therapies for patients worldwide.
Revolutionizing Drug Discovery: FogPharma Secures $145 Million in Funding for Breakthrough HeliconTM Peptides
Get the full FogPharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Lassie
Lassie enables doctors to focus on patients, not paperwork. The average practice spends around 200 hours a month running itself. We have seen firsthand how the administrative burden is quietly breaking independent healthcare. Doctors work late into the night so that they can get through all of their paperwork by hand. Nobody taught them how to submit a claim, bill a patient, or reconcile insurance payments. Our goal is to enable these businesses to run themselves. Lassie works autonomously, around the clock, reading insurance claims, reconciling payments, handling denials and appeals. Over 700 practices across 49 states trust Lassie to run their operations. In the past year alone, we have saved more than 250,000 hours of labor, time redirected entirely to patient care. Learn more or join the team: lassie.ai
$35.0M Unknown
today
GR3N SA
GR3N SA is a Swiss company founded in 2011 that developed an innovative process, based on the application of microwave technology to an alkaline hydrolysis, which provides an economically viable recycling process of Polyethylene Terephthalate (PET), allowing the industrial implementation. This new process can potentially change how PET is recycled worldwide, with huge benefits both for the recycling industry and for all the polyester value chain. In the past, many efforts were made to transfer chemical recycling from research labs to industry but the economic aspects blocked the proposed solutions. Thanks to the DEMETO (Depolymerization by MicrowavE TechnolOgy) technology developed by gr3n this approach becomes real. gr3n has a massive advantage with respect to its competitors because it can supply a chemical recycling solution (i.e., closing the PET lifecycle, offering polymer grade material, treating waste, lowering carbon footprint) providing cost savings for players in the value chain. The input materials for the process can be post-consumer and/or post-industrial polyesters, both from bottles (colored, colorless, transparent, opaque) and textile (100% polyester but also with up to 30% of other materials like PU, cotton, polyether-polyurea, etc.). The reaction output is a mixture of building block derivatives, which are then isolated and purified. Monomers can be endlessly re-polymerized to provide brand-new virgin PET or any other polymer that is using one of the monomers. As mentioned for the depolymerization step, every time we run a polymerization, we obtain a brand new polymer, where the technical features depend on the monomer purity and the polymerization conditions.
$15.5M Series b
today
phab
phab was born from a single question we’ve asked ourselves for years: why do we have to choose between healthy and tasty? life is complicated as is. our snacks shouldn’t be. ?♂️ and so, with a nutritionist at the helm, scientists by our side, and major foodies in the team, we decided to make snacking superheroes that prove you can have the best of both worlds. ? our mission is to help each of us make that easy switch to better snacking. with 80% of Indians being deficient in protein, we put the macronutrient at the forefront of our protein-powered snack revolution. with phab, you get no trans fats, no GMOs, no harmful sugars, no cutting corners, no BS. just all of the good stuff and none of the guilt. ? our range of products includes: milkshakes + protein, energy and granola bars + protein and superfood bombs + protein powders ?find us in major grocery stores or online marketplaces across India ? learn more at getphab.com ? follow us at instagram.com/getphab
$4.0M Series a
today
Radley Health
RadleyCare’s mission is to enable adults with severe mental illness, and their families, to live amazing lives. Our long term vision is to offer a full suite of psychiatric services to patients, which will improve quality of life and simultaneously decrease the total cost of healthcare. Our entry point is through Peer Recovery Support and Family Peer Support. We couldn't be more excited to bring these valuable services to more people in the State of Ohio. Please join us on our journey to live amazing lives.
$3.0M Seed
today
Arpio
Arpio protects cloud environments from catastrophic events such as outages and ransomware attacks with comprehensive, automated disaster recovery in AWS & Azure.
$15.0M Series a
today